Reinnervate Ltd announce Kirkstall Ltd collaboration
30 March 2012
Reinnervate (inventors of Alvetex® Scaffold) and Kirkstall (developers of the Quasi-Vivo® system) today announced that they will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012.
Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®
16 November 2011
Read today's announcement that Reinnervate and Mirus Bio have entered into a commercial agreement to launch a new range of 3d cell culture products.
Alvetex® voted one of most technologically significant new research products by R&D magazine
27 June 2011
Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.
Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine
06 December 2010
Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of The Scientist magazine’s“Top 10 Life Science Innovations of 2010”.
Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture
22 November 2010
Reinnervate, is very pleased to announce today the first commercial launch of Alvetex®, its breakthrough 3D cell culture technology. find out more.
Reinnervate completes expansion into new purpose-built facility at NETPark
17 November 2010
Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.
Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells
28 September 2010
Read more about Reinnervate’s ec23 and its ability to enhance neuronal differentiation as demonstrated in a paper published in Neuroscience Methods.
Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells
28 September 2010
Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold optimised for 3D hepatocyte culture.
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)
14 September 2010
Reinnervate has been accepted into the In Vitro Testing Industrial Platform, advising European bodies on research projects in in vitro testing.
Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex
27 May 2010
Reinnervate has successfully raised £1.8 million in new equity funding to complete the development of its Alvetex® 3D cell culture platform.